Cergentis is a genomics-focused biotech company that developed and patented Targeted Locus Amplification (TLA). TLA is a widely published Next Generation Sequencing (NGS) technology that enables targeted and complete sequencing of (trans)genes and gene editing events. With innovative services and in-house solutions, Cergentis has established itself as leader and trusted partner in robust and rapid genetic characterization of genetically engineered cell lines, cell and gene therapy products and transgenic (animal) models for the global biopharmaceutical industry as well as leading research institutes. It is our mission to improve the quality of genetic research. By supporting biopharmaceutical R&D, we accelerate the development and guarantee the genetic quality of new treatments resulting in better outcomes for patients all over the world.
